Compare Incyte Corporation (INCY) vs Mongodb Inc (MDB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Mongodb Inc — how do they compare? Incyte Corporation trades at $120.8 (market cap $24.54B), while Mongodb Inc trades at $439.22 (market cap $35.32B). The key difference: Mongodb Inc is the larger of the two by market cap, and Mongodb Inc is trading nearer its 52-week high, Incyte Corporation nearer its low. Which is the better fit depends on your goals.
| INCY | MDB | |
|---|---|---|
Market Cap | $24.54B | $35.32B |
Sector | Health | Technology |
52-Week High | $129.93 | $440.25 |
52-Week Low | $81.61 | $204.37 |
Enterprise Value | $20.04B | $32.93B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.93, down 0.51% on the day, near its 52-week high. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $3.09 versus $2.15 expected, driven by robust Jakafi and Opzelura sales. Revenue growth accelerated to $5.14 billion in 2025, with net income margin expanding to 27.71%. Technical indicators signal a bullish trend with moving averages supporting upside, while oscillators remain neutral.
Outlook remains positive given raised 2026 revenue guidance and recent EU approval for Opzelura, though risks include competitive pressures and reliance on key products. Analyst consensus is bullish with a $122.82 price target, implying modest upside from current levels amid solid institutional ownership trends.
MongoDB (MDB) trades at $439.54, up 5.49% on the day. The stock exhibits a bullish technical trend, with moving averages and overall signals supporting a buy stance, though oscillators show mixed signals. Fundamentally, revenue growth is strong, reaching $2.01B in 2025, but the company remains unprofitable with a net income margin of -1.12%. Recent earnings have consistently beaten expectations, and analyst sentiment is overwhelmingly positive with 81.81% buy ratings.
The outlook for MDB is optimistic due to robust revenue growth and AI-driven demand, but risks include persistent losses and high valuation multiples. The consensus price target of $404.30 suggests potential downside from current levels, indicating caution despite bullish sentiment. Investors should weigh growth prospects against profitability challenges and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Mongodb Inc
Founded in 2007, MongoDB is a document-oriented database with nearly 33,000 paying customers and well past 1.5 million free users. MongoDB provides both licenses as well as subscriptions as a service for its NoSQL database. MongoDB's database is compatible with all major programming languages and is capable of being deployed for a variety of use cases.
Read more on MDB →
